NASDAQ:CTHR Charles & Colvard, Ltd. (CTHR) Stock Price, News & Analysis $0.50 -0.25 (-33.33%) As of 03:27 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Charles & Colvard, Ltd. Stock (NASDAQ:CTHR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CTHR alerts:Sign Up Key Stats Today's Range$0.35▼$0.7850-Day Range$0.21▼$0.9852-Week Range$0.00▼$2.30Volume3,878 shsAverage Volume32,721 shsMarket Capitalization$1.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Charles & Colvard Ltd. engages in the manufacture and distribution of moissanite jewels and finished jewelry featuring moissanite for sale in the worldwide jewelry market. It operates through the following business segments: Online Channels and Traditional. The Online Channels segment refers to the e-commerce outlets, including charlesandcolvard.com, third-party online marketplaces, drop-ship, other pure-play, and e-commerce outlets. The Traditional segment consists of wholesale and retail customers. The company was founded in 1995 and is headquartered in Morrisville, NC. Read More Receive CTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Charles & Colvard, Ltd. and its competitors with MarketBeat's FREE daily newsletter. Email Address CTHR Stock News HeadlinesCharles & Colvard, Ltd. (CTHR) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comCharles & Colvard, Ltd. (CTHR) stock price, news, quote & history – Yahoo FinanceJuly 2, 2025 | au.finance.yahoo.comBiotech Alert: With news on MPox, RSV, and more, this tiny firm could disrupt a $3B marketA small biotech is stepping into the spotlight with a first-in-class antiviral platform—and it could be one of the market’s most overlooked opportunities today. NanoViricides, Inc. (NYSE: NNVC) is advancing NV-387, a broad-spectrum antiviral now in human trials, with activity against COVID-19, RSV, influenza, measles, and most recently Mpox. With Phase II trials approved in Africa for the deadliest Mpox strain, the timing couldn’t be more critical.August 18 at 2:00 AM | Smallcaps Daily (Ad)Charles & Colvard Delays Quarterly Report FilingMay 16, 2025 | tipranks.comCharles & Colvard announces delisting from NasdaqApril 24, 2025 | msn.comCharles & Colvard Faces Nasdaq Delisting by April 25April 22, 2025 | tipranks.comCharles & Colvard, Ltd. Announces Delisting from NasdaqApril 22, 2025 | prnewswire.comCharles & Colvard, Ltd. Receives Expected Nasdaq Notice Regarding Delayed Form 10-QMarch 3, 2025 | prnewswire.comSee More Headlines CTHR Stock Analysis - Frequently Asked Questions How have CTHR shares performed this year? Charles & Colvard, Ltd.'s stock was trading at $1.33 at the beginning of the year. Since then, CTHR shares have decreased by 73.7% and is now trading at $0.3503. How were Charles & Colvard, Ltd.'s earnings last quarter? Charles & Colvard, Ltd. (NASDAQ:CTHR) issued its quarterly earnings data on Thursday, November, 4th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.10. The company earned $10.28 million during the quarter, compared to analysts' expectations of $9.20 million. Read the conference call transcript. When did Charles & Colvard, Ltd.'s stock split? Charles & Colvard, Ltd. shares reverse split on Friday, May 17th 2024.The 1-10 reverse split was announced on Friday, May 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Charles & Colvard, Ltd.? Shares of CTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Charles & Colvard, Ltd. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Charles & Colvard, Ltd. investors own include Zoom Communications (ZM), Fulgent Genetics (FLGT), Alphabet (GOOG), Meta Platforms (META), Splunk (SPLK), Fiverr International (FVRR) and Shopify (SHOP). Company Calendar Last Earnings11/04/2021Today8/18/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorConsumer Discretionary Industry Jewelry, silverware, & plated ware Sub-IndustryConsumer Goods Current SymbolNASDAQ:CTHR CIK1015155 Webwww.charlesandcolvard.com Phone(919) 468-0399Fax919-468-0486Employees60Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$21.96 million Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$13.03 per share Price / Book0.06Miscellaneous Outstanding Shares3,118,000Free Float2,351,000Market Cap$2.43 million OptionableNot Optionable Beta2.59 Social Links 10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:CTHR) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored"AI Upgrade" Coming Sept. 1stA new “AI Upgrade” is rolling out on September 1st—and tech leaders are calling it transformational. Softbank’...Behind the Markets | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredAmericans are rushing into gold (but not billionaires!)Billionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Charles & Colvard, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Charles & Colvard, Ltd. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.